EMA goes PRO, seeks more patient input in regulatory process
By Nuala Moran
Friday, June 20, 2014
LONDON The EMA has launched a consultation on factoring patient-related outcomes into the regulatory process for oncology drugs, as a next step in its efforts to turn patient sentiment into hard data and speed up its approval processes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.